
ANDREW R. WILLAN

ANDREW H. BRIGGS

Statistical Analysis

of Cost-effectiveness Data



WILEY

STATISTICS IN PRACTICE

Copyright © 2006

John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SO, England

Telephone (+44) 1243 779777

Email (for orders and customer service enquiries): cs-books@wiley.co.uk Visit our Home Page on www.wiley.com

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, or emailed to permreq@wiley.co.uk, or faxed to (+44) 1243 770620.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The Publisher is not associated with any product or vendor mentioned in this book.

This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the Publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

Other Wiley Editorial Offices

John Wiley & Sons Inc., 111 River Street, Hoboken, NJ 07030, USA

Jossey-Bass, 989 Market Street, San Francisco, CA 94103-1741, USA

Wiley-VCH Verlag GmbH, Boschstr. 12, D-69469 Weinheim, Germany

John Wiley & Sons Australia Ltd, 42 McDougall Street, Milton, Queensland 4064. Australia

John Wiley & Sons (Asia) Ptc Ltd. 2 Clementi Loop #02-01, Jin Xing Distripark, Singapore 129809

John Wiley & Sons Canada Ltd, 22 Worcester Road, Etobicoke, Ontario, Canada M9W 1L1

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Library of Congress Cataloging-in-Publication Data

(to follow)

British Library Cataloguing in Publication Data

A catalogue record for this book is available from the British Library

ISBN-13 978-0-470-85626-0 (HB) ISBN-10 0-470-85626-2 (HB)

Typeset in 11/13pt Photina by TechBooks, New Delhi, India Printed and bound in Great Britain by TJ International Ltd, Padstow, Cornwall This book is printed on acid-free paper responsibly manufactured from sustainable forestry in which at least two trees are planted for each one used for paper production.

For Bernie

All author proceeds donated to the Emma and Lucy O'Brien Education Fund.

Contents

Pre	face				xi	
1	Col	ncept	sesigumadi selegius A secometicalioni		1	
	1.1 1.2 1.3 1.4	Introduction Cost-effectiveness data and the parameters of interest The cost-effectiveness plane, the ICER and INB Outline				
2	Par	rame	ter Estimation for Non-censored Data		11	
	2.1 2.2 2.3	Introde Cost 2.2.1 2.2.2 2.2.3 2.2.4 2.2.5 2.2.6 Effective 2.3.1 2.3.2 2.3.3 2.3.4 Summ	Sample means for estimating incremental cost Using multiple regression models Transformation (and the retransformation problem) Generalized linear models Two-part models for excess zeros Cost prediction models veness Probability of surviving Mean survival time Mean quality-adjusted survival time Mean quality-adjusted survival: controlling for baseline utility		11 12 12 14 15 17 18 19 20 21 21 22 24 25	
3	Parameter Estimation for Censored Data					
	3.1 3.2 3.3	3.2.2 Effecti			27 28 29 31 34 34	

3.3.2 Mean survival time 3.3.3 Mean quality-adjusted survival time 3.4 Summary 4 Cost-effectiveness Analysis 4.1 Introduction 4.2 Incremental cost-effectiveness ratio 4.3 Incremental net benefit 4.4 The cost-effectiveness acceptability curve 4.5 Using bootstrap methods 4.6 A Bayesian incremental net benefit approach 4.7 Kinked thresholds 4.8 Summary 5 Cost-effectiveness Analysis: Examples 5.1 Introduction 5.2 The CADET-Hp trial 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial 5.6 Bayesian approach applied to the UK PDS study	36 39 42
4 Cost-effectiveness Analysis 4.1 Introduction 4.2 Incremental cost-effectiveness ratio 4.3 Incremental net benefit 4.4 The cost-effectiveness acceptability curve 4.5 Using bootstrap methods 4.6 A Bayesian incremental net benefit approach 4.7 Kinked thresholds 4.8 Summary 5 Cost-effectiveness Analysis: Examples 5.1 Introduction 5.2 The CADET-Hp trial 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial	
 4 Cost-effectiveness Analysis 4.1 Introduction 4.2 Incremental cost-effectiveness ratio 4.3 Incremental net benefit 4.4 The cost-effectiveness acceptability curve 4.5 Using bootstrap methods 4.6 A Bayesian incremental net benefit approach 4.7 Kinked thresholds 4.8 Summary 5 Cost-effectiveness Analysis: Examples 5.1 Introduction 5.2 The CADET-Hp trial 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial 	42
 4.1 Introduction 4.2 Incremental cost-effectiveness ratio 4.3 Incremental net benefit 4.4 The cost-effectiveness acceptability curve 4.5 Using bootstrap methods 4.6 A Bayesian incremental net benefit approach 4.7 Kinked thresholds 4.8 Summary 5 Cost-effectiveness Analysis: Examples 5.1 Introduction 5.2 The CADET-Hp trial 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial 	
 4.2 Incremental cost-effectiveness ratio 4.3 Incremental net benefit 4.4 The cost-effectiveness acceptability curve 4.5 Using bootstrap methods 4.6 A Bayesian incremental net benefit approach 4.7 Kinked thresholds 4.8 Summary 5 Cost-effectiveness Analysis: Examples 5.1 Introduction 5.2 The CADET-Hp trial 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial 	43
 4.3 Incremental net benefit 4.4 The cost-effectiveness acceptability curve 4.5 Using bootstrap methods 4.6 A Bayesian incremental net benefit approach 4.7 Kinked thresholds 4.8 Summary 5 Cost-effectiveness Analysis: Examples 5.1 Introduction 5.2 The CADET-Hp trial 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial 	43
 4.4 The cost-effectiveness acceptability curve 4.5 Using bootstrap methods 4.6 A Bayesian incremental net benefit approach 4.7 Kinked thresholds 4.8 Summary 5 Cost-effectiveness Analysis: Examples 5.1 Introduction 5.2 The CADET-Hp trial 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial 	44
 4.5 Using bootstrap methods 4.6 A Bayesian incremental net benefit approach 4.7 Kinked thresholds 4.8 Summary 5 Cost-effectiveness Analysis: Examples 5.1 Introduction 5.2 The CADET-Hp trial 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial 	49
 4.6 A Bayesian incremental net benefit approach 4.7 Kinked thresholds 4.8 Summary 5 Cost-effectiveness Analysis: Examples 5.1 Introduction 5.2 The CADET-Hp trial 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial 	51
 4.7 Kinked thresholds 4.8 Summary 5 Cost-effectiveness Analysis: Examples 5.1 Introduction 5.2 The CADET-Hp trial 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial 	54
 5 Cost-effectiveness Analysis: Examples 5.1 Introduction 5.2 The CADET-Hp trial 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial 	57
 5 Cost-effectiveness Analysis: Examples 5.1 Introduction 5.2 The CADET-Hp trial 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial 	60
 5.1 Introduction 5.2 The CADET-Hp trial 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial 	64
 5.2 The CADET-Hp trial 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial 	67
 5.3 Symptomatic hormone-resistant prostate cancer 5.4 The Canadian implantable defibrillator study (CIDS) 5.5 The EVALUATE trial 	67
5.4 The Canadian implantable defibrillator study (CIDS)5.5 The EVALUATE trial	67
5.4 The Canadian implantable defibrillator study (CIDS)5.5 The EVALUATE trial	72
	77
5 6 Rayagian approach applied to the III/ DDG -	82
	86
5.7 Summary	90
6 Power and Sample Size Determination	93
6.1 Introduction	93
6.2 Approaches based on the cost-effectiveness plane	94
6.2.1 Briggs and Gray	95
6.2.2 Willan and O'Brien	98
6.2.3 Gardiner et al.	101
6.3 The classical approach based on net benefit	103
6.3.1 The method	103
6.3.2 Example	105
6.4 Bayesian take on the classical approach	106
6.4.1 The Method	106
6.4.2 Example 6.5 The value of information approach	107
6.5 The value of information approach 6.5.1 The method	108
6.5.2 Example	108
6.6 Summary	114
olo bullinary	116
7 Covariate Adjustment and Sub-group Analysis	117
7.1 Introduction	111
7.2 Non-censored data	
7.2.1 Example, non-censored data	117 118

				Contents	ix
	7.3	Consor	red data		129
	7.5	7.3.1	Cost		131
			Quality-adjusted survival time		132
		7.3.3	Survival time		134
		7.3.4	The Canadian implantable defibrillator study (CIDS)		135
			The evaluate trial		138
	7.4	Summ			142
8	Mu	ltice	nter and Multinational Trials		145
	8.1	Introd	vation		145
	8.2		round to multinational cost-effectiveness		147
	8.3		effect approaches		151
	0.3		Willke et al.		151
		8.3.2	Cook et al.		152
	8.4		om effects approaches		154
	0.4		Aggregate level analysis: multicenter trials		154
		8.4.2	Aggregate level analysis: multinational trials		156
1		8.4.3	Hierarchical modeling		162
	8.5	Summ	_		164
9	Mo	delir	ng Cost-effectiveness		165
	9.1	Introd	uction		165
	9.2		eral framework for modeling cost-effectiveness results		166
	9.3	_	tudy: an economic appraisal of the goal study		167
	,,,	9.3.1	The GOAL study		168
		9.3.2	Standard approach to estimating cost-effectiveness		170
			An alternative approach to estimating cost-effectiven	ess	171
		9.3.4	Comparing the two analyses of GOAL		179
	9.4	Summ	nary		180
Re		183			
Au		193			
Su	bjec	t Inde	X		195
Sei	ries l	List			197

Preface

This book describes statistical methods applied to cost-effectiveness analysis. It represents the experience over many years of the author's involvement in the application and methodology of health economic evaluation. The focus on randomised clinical trials reflects the fact that the trend towards collecting not only clinical, but also economic, data alongside clinical trials was the driving force behind many of the methodological developments described in the text. Health economics is a relatively young discipline and the use of clinical trials as a vehicle for economic evaluations began in earnest only twenty years ago. As a consequence, there has been a high degree of methodological development since then, with most of the reporting confined to journal articles. The aim of this book is to draw together those developments in a single source which we hope will be of interest to students of statistics, keen to understand more about health economics, and students of health economics, keen to understand the statistical methods required for undertaking economic evaluation of health care interventions. The exposition is at a technical level roughly equivalent to that found in final year undergraduate mathematics and statistics courses or postgraduate social sciences courses.

The book itself naturally divides into two parts. The first part (up to Chapter 5) deals with the established approach for the presentation of cost-effectiveness analyses, with a focus on estimating health outcomes and resource use costs. The second part of the book (Chapters 6 through 9) handles specific issues in more depth to give a fuller understanding of the nuances of a modern cost-effectiveness analysis where patient-level data are available.

xii Preface

In the preparation of any book there are numerous colleagues and students who have provided the inspiration and insight, as well as friends and family who have provided the encouragement and support, necessary to bring such a project to fruition. We are extremely grateful to all those people who have helped us over the years and aided us to a greater or lesser extent in supporting our endeavours and correcting our mistakes. However, one person stands out as the true inspiration for this book. A friend and colleague who had a major influence on both of our careers in the area of health economic evaluation, albeit in different ways, Bernie O'Brien was a rare person – someone with a keen intellect, an infectious enthusiasm, and a generosity of ideas that could not fail to rub off on those around him. His untimely death on the 13th of February, 2004 was a terrible shock and leaves a vacuum in the health economics community, as well as for his wife Karen and daughters, Emma and Lucy. We dedicate this book to Bernic's memory.